Duration of the Haemodynamic Action of a 24-h Infusion of Levosimendan in Patients with Congestive Heart Failure
Authors:
- 1 January 2007
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Heart Failure
- Vol. 9 (1) , 75-82
Abstract
Aims: To determine the duration of haemodynamic and neurohormonal action of a 24-h infusion of levosimendan in heart failure. Methods and results: This was a double-blind, parallel group study in patients with New York Heart Association class II to IV heart failure. Twenty-two patients, with left ventricular ejection fraction <35% and pulmonary capillary wedge pressure (PCWP) above 12 mmHg, were randomised to receive either levosimendan (12 μg/kg followed by a continuous infusion of 0.1–0.2 μg/min) or placebo. Invasively measured cardiac output (CO) increased from 4.3 l/min to 5.4 l/min in the levosimendan group at 6 h. PCWP decreased from 20 mmHg to 15 mmHg in response to levosimendan. Echocardiographically measured maximal effect on PCWP occurred after 6 h, whereas CO reached its highest value at 24 h. The estimated duration of the decrease in PCWP was 7–9 days, and in CO was 12–13 days. Plasma NT-proANP and NT-proBNP levels reached their lowest values at days 3 and 2, and the treatment effect was estimated to last 16 and 12 days, respectively. The long-acting haemodynamic responses reflect levels of the active metabolites OR-1896 and OR-1855, maximal metabolite levels occurred at day 3. Conclusions: Levosimendan infusion achieved a rapid improvement in haemodynamic parameters in patients with congestive heart failure with maximal effects occurring 1–3 days after starting the infusion, effects were sustained for up to at least a week.Keywords
This publication has 20 references indexed in Scilit:
- Diagnosing heart failure in aortic valve stenosisJournal of Internal Medicine, 2004
- Molecular Heterogeneity Has a Major Impact on the Measurement of Circulating N-Terminal Fragments of A- and B-Type Natriuretic PeptidesClinical Chemistry, 2004
- Pharmacokinetics of levosimendan and its circulating metabolites in patients with heart failure after an extended continuous infusion of levosimendanBritish Journal of Clinical Pharmacology, 2004
- Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): a randomised double-blind trialThe Lancet, 2002
- Binding of Levosimendan, a Calcium Sensitizer, to Cardiac Troponin CJournal of Biological Chemistry, 2001
- Comparison of the Vasorelaxing Effect of Cromakalim and the New Inodilator, Levosimendan, in Human Isolated Portal VeinJournal of Pharmacy and Pharmacology, 2000
- Doppler evaluations of left ventricular diastolic filling and pulmonary wedge pressure provide similar prognostic information in patients with systolic dysfunction after myocardial infarctionAmerican Heart Journal, 1995
- Pharmacokinetics of Levosimendan in Healthy Volunteers and Patients with Congestive Heart FailureJournal of Cardiovascular Pharmacology, 1995
- Dose-Range Study of a New Calcium Sensitizer, Levosimendan, in Patients with Left Ventricular DysfunctionJournal of Cardiovascular Pharmacology, 1995
- Pulsed Doppler echocardiographic determination of stroke volume and cardiac output: clinical validation of two new methods using the apical window.Circulation, 1984